Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosisMinoru Nakamura, Hiromi Ishibashi, Hisayoshi Kondo et al.|Hepatology|2006Cited by 365
Long-Term Clinical Outcomes After Everolimus- and Sirolimus-Eluting Coronary Stent ImplantationHiroki Shiomi, Takeshi Kimura, Satoru Suwa et al.|Circulation Cardiovascular Interventions|2014Cited by 41
7-Year Outcomes of a Randomized Trial Comparing the First-Generation Sirolimus-Eluting Stent Versus the New-Generation Everolimus-Eluting StentHiroki Shiomi, Takeshi Kimura, Ken Kozuma et al.|JACC: Cardiovascular Interventions|2019Cited by 29
Impact of Angiographic Residual Stenosis on Clinical Outcomes After New‐Generation Drug‐Eluting Stents Implantation: Insights From a Pooled Analysis of the RESET and NEXT TrialsHiroki Watanabe, Takeshi Morimoto, Hiroki Shiomi et al.|Journal of the American Heart Association|2018Cited by 25
Second-Generation vs. First-Generation Drug-Eluting Stents in Patients With Calcified Coronary Lesions ― Pooled Analysis From the RESET and NEXT Trials ―Koji Nishida, Kenji Nakatsuma, Hiroki Shiomi et al.|Circulation Journal|2017Cited by 17